drugset
drugset / Trial / NCT07093710

Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma

NCT07093710 ↗

Phase 1/2 Recruiting 101 enrolled Sun Yat-sen University
NaSingle-groupOpen-labelTreatment

Summary

This is a prospective, multicenter, open-label, phase Ib/II clinical study to evaluate the safety and efficacy of golidocitinib combined with mitoxantrone hydrochloride liposome or chidamide in the treatment of relapsed or refractory peripheral T-cell lymphoma

Timeline

Start
2025-08-27
Primary completion
2027-08-01
Completion
2029-08-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Golidocitinib Small molecule 150 mg Oral
Subject Mitoxantrone Small molecule 15 mg/m2 Intravenous
Subject Mitoxantrone Small molecule 18 mg/m2 Intravenous
Subject Tucidinostat Small molecule 20 mg Oral
Subject Tucidinostat Small molecule 30 mg Oral

Indications

peripheral T-cell lymphoma, not otherwise specified